A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
NCT02923349
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
87
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Malignancies
Metastatic Cancer
Interventions
DRUG:
INCAGN01949
Sponsor
Incyte Biosciences International Sàrl